| # | Drug | Count |
|---|---|---|
| 0 | ECULIZUMAB | 1589 |
| 1 | PREDNISONE | 1110 |
| 2 | CYCLOPHOSPHAMIDE | 1105 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 1105 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 1105 |
| 5 | RITUXIMAB | 1046 |
| 6 | PREDNISOLONE ORAL SOLUTION | 835 |
| 7 | PREDNISOLONE | 834 |
| 8 | PREDNISOLONE ORAL | 834 |
| 9 | DEXAMETHASONE 1.5 MG | 784 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | POLATUZUMAB VEDOTIN | 419 | 0.0411 |
| 1 | ECULIZUMAB | 1589 | 0.0292 |
| 2 | VANCOMYCIN HYDROCHLORIDE | 216 | 0.0258 |
| 3 | BENDAMUSTINE HCL | 377 | 0.0241 |
| 4 | BENDAMUSTINE HYDROCHLORIDE | 182 | 0.0214 |
| 5 | IFOSFAMIDE FOR INJECTION | 226 | 0.0105 |
| 6 | DOXORUBICIN HYDROCHLORIDE | 307 | 0.0093 |
| 7 | OBINUTUZUMAB | 147 | 0.0087 |
| 8 | HYDROXYUREA | 184 | 0.0086 |
| 9 | CYTARABINE | 512 | 0.0084 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 2722 |
| 1 | Complement Inhibitor [EPC] | 1626 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 1553 |
| 3 | Alkylating Drug [EPC] | 1267 |
| 4 | CD20-directed Cytolytic Antibody [EPC] | 1066 |
| 5 | Platinum-based Drug [EPC] | 1010 |
| 6 | Kinase Inhibitor [EPC] | 987 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 978 |
| 8 | Loop Diuretic [EPC] | 825 |
| 9 | Benzodiazepine [EPC] | 746 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Complement Inhibitor [EPC] | 1626 | 0.0289 |
| 1 | CD33-directed Immunoconjugate [EPC] | 65 | 0.0177 |
| 2 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 58 | 0.0143 |
| 3 | CD30-directed Immunoconjugate [EPC] | 85 | 0.0082 |
| 4 | CD22-directed Immunoconjugate [EPC] | 20 | 0.0067 |
| 5 | Topoisomerase Inhibitor [EPC] | 470 | 0.0061 |
| 6 | Iron Chelator [EPC] | 176 | 0.0060 |
| 7 | Histone Deacetylase Inhibitor [EPC] | 22 | 0.0057 |
| 8 | CD19-directed Chimeric Antigen Receptor [EPC] | 57 | 0.0056 |
| 9 | Alkylating Drug [EPC] | 1267 | 0.0052 |